FindTrial
Sign In

Role of erectile stimulant (Tadalafil) in relieving chronic pelvic pain

Role of PDE 5 inhibitor in the treatment of chronic pelvic pain syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/08/007208
Enrollment
42
Registered
2016-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of chronic pelvic pain syndrome in good general condition

Interventions

Intervention1: Capsule Tadalafil: Treatment group will be given Tab tadalafil 5mg OD in once daily dose for 6 weeks along with Tab Levofloxacin 500mg OD for 6 weeks and Tab Alfuzosin 10 mg OD x 6 we

Sponsors

All India Institute Of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients diagnosed to have chronic prostatitis or chronic pelvic pain syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
IPSS,NIH-CPSI,and IIEF Score along with uroflometer reading before and after starting treatments in both the groupsTimepoint: 6 weeks—

Secondary

MeasureTime frame
Any side effects, UTI,fever Timepoint: 6weeks—

Countries

India

Contacts

Public ContactAbhishek Kumar Shukla

AIIMS

drprabhjotsingh@gmail.com9350773275

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026